Resultados de la búsqueda 1121-1130 of 5512 for Grow
This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this ...
Rochester, Minn. This study aims to demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior ...
This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small ...
The purpose of this study is to evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. Eligible patients with surgically ...
This study aims to evaluate the outcomes and patient satisfaction with same day mastectomy with or without alloplastic reconstruction following COVID-19 and ...
The purpose of this study is to assemble a collection of serial plasma biospecimens from women with ovarian, primary peritoneal, or fallopian tube cancer ...
The purposes of this study are (i) to obtain and study biospecimens from patients with breast cancer that has either spread out of the breast or recurred ...
The purpose of this study is to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a ...
Lymphoma is a diversified disease with outcomes differing upon the types and subtypes of lymphoma as well as treatment modalities used. Fertility outcomes in ...
The purpose of this study is to culture human mammary cells to identify cellular characteristics associated with lobular involution status. Cutaneous Lymphoma ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?